All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Looking to reach an audience of 1600+ biotech and pharma professionals? Let’s chat. 👍

THE GOOD
Approvals & Labels

Sanofi's Sarclisa (anti-CD38) lands EC approval (with VRd) for newly diagnosed multiple myeloma
Monoclonal antibody, multiple myeloma, cancer - Read more

THE GOOD
Business Development

ArriVent BioPharma pays Lepu Biopharma $47M upfront for preclinical ADC cancer drug MRG007, with potential future payments up to $1.16B
Antibody-drug conjugate, gastrointestinal cancer - Read more

Kindeva subsidiary Meridian Medical wins $129M US contract to supply DuoDote nerve agent antidote autoinjectors.
Small molecule, nerve agent antidote, insecticide exposure - Read more

THE GOOD
Clinical Trials

Tris Pharma's cebranopadol (targeting NOP/MOP receptors) delivers Ph3 win as non-opioid painkiller for post-abdominoplasty pain management
Small molecule, post-abdominoplasty pain management - Read more

Lisata Therapeutics touts “encouraging” early Ph2 data for certepetide in metastatic pancreatic ductal adenocarcinoma treatment
Bifunctional peptide, pancreatic ductal adenocarcinoma, cancer - Read more

Artax Biopharma showcase “clinical validation” Ph2a data for AX-158 (Nck modulator) in plaque psoriasis
Small molecule, plaque psoriasis - Read more

Coherus BioSciences delivers final Ph2 data for casdozokitug (IL-27 inhibitor) in combo with atezolizumab/bevacizumab in treating metastatic liver cancer
Monoclonal antibody, liver cancer - Read more

Salubris Biotherapeutics touts positive interm Ph2 data for JK07 (ErbB4 agonist) in heart failure with reduced and preserved ejection fraction
Recombinant fusion protein, heart failure - Read more

Anthos Therapeutics' abelacimab (Factor XI/XIa inhibitor) delivers positive Ph2 versus incumbent Xarelto (Bayer, Janssen) in reducing bleeding events in patients with atrial fibrillation
Small molecule, atrial fibrillation - Read more

Intellia Therapeutics doses first patient in Ph3 trial of gene-editing therapy NTLA-2002 (targeting kallikrein B1) for hereditary angioedema treatment
Gene-editing, hereditary angioedema, CRISPR - Read more

THE GOOD
Earnings & Finances

Cancer drug Darzalex becomes Johnson & Johnson's top seller at $11.7B annually, while depression treatment Spravato reaches $1.1B in sales
Monoclonal antibody, cancer, small molecule, depression - Read more

Samsung Biologics achieves record profits in 2024, with 18.5% increase in operating profit from contract drug manufacturing business
CDMO, contract manufacturing - Read more

Johnson & Johnson expects 3% growth despite Stelara biosimilar competition, banking on newer drugs like Tremfya to maintain sales momentum
Monoclonal antibody, plaque psoriasis, Crohn’s disease - Read more

THE GOOD
Fundraises

Lindus Health $55M Series B, clinical trial optimization platform making trials faster and more reliable
CRO, contract research - Read more

Disc Medicine $200M public offering, developing treatments for blood diseases
Small molecule, monoclonal antibody, erythropoietic protoporphyria, X-linked protoporphyria, anemia - Read more

Exsure Rs 3 Cr ($350K) Seed raise, exosome-enabled tech to reduced cancer med toxicity/side effects
Exosomes, cancer, drug delivery, side effect reduction - Read more

PRESENTED BY YOU?
Get the attention of 1600+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

⬇️ More Good News ⬇️

THE GOOD
IPOs

Chinese biotech firms Biokin Pharmaceutical and Bao Pharmaceuticals seek Hong Kong IPO listings amid growing domestic pharmaceutical industry influence
Antibody-drug conjugate, small molecule, cancer - Read more

Beta Bionics aims for $616M valuation in IPO, plans to sell 7.5M shares amid recovering medtech market
Medical device, type 1 diabetes, artificial pancreas - Read more

THE GOOD
Mergers & Acquisition

Crown Laboratories increases acquisition offer for Revance Therapeutics to $3.65 per share, extending tender deadline to February 4, 2025
Aesthetics, skin care, dermal filler - Read more

Vaxcell Bio acquires ALBiotek, gaining bispecific antibody platform and drug delivery technology to enhance cancer treatment development.
Bispecific antibody, cancer, drug deliver - Read more [Press release in Korean]

THE GOOD
Partnerships

IMMvention Therapeutix, Novo Nordisk partner to develop oral BACH1 inhibitors for sickle cell disease treatment
Small molecule, sickle cell disease, drug development - Read more

GI Innovation, LaNova Medicines partner to develop GI-102 and ADC combination therapy for pancreatic cancer treatment
Fusion protein, antibody-drug conjugate, pancreatic cancer, drug development - Read more

Conduit Pharmaceuticals, Agility Life Sciences partner to develop enhanced oral formulations for autoimmune drug pipeline
Drug delivery, autoimmune - Read more

THE GOOD
Politics & Policy

RFK Jr. promises to sell his CRISPR Therapeutics and Dragonfly Therapeutics investments if confirmed as HHS Secretary
Gene-editing, CRISPR, conflict of interest, Department of Health & Human Services - Read more

THE GOOD
Product Launches

Advarra launches digital platform combining Longboat portal with startup tools to accelerate clinical trial initiation and site-sponsor collaboration.
CRO, clinical trial initiation, clinical trial enrolment - Read more

THE GOOD
Opinions

Regeneron's CSO George Yancopoulos compares AI hype to unfulfilled stem cell promises, urging caution about revolutionary medical claims
Drug development, drug discovery, AI, hype - Read more

THE GOOD
Strategic Plans

Takeda adjusts R&D strategy amid economic changes, focusing on late-stage pipeline while adapting to new healthcare legislation.
Research & development - Read more

Incyte CEO outlines 18 key events for 2025, including four product launches and pivotal trial results, while seeking strategic deals.
Commercialization strategy - Read more

ENJOYING THESE NEWSLETTERS?
Support TLDR Biotech🧬🦠🔬

I’m offering this newsletter for free so it can get out to as many people as possible.

If you’re getting value out of these daily compilations, please consider a paid subscription (only $5/month) to support my continued work on this project.*

*Best of all, it’s a work-related news source that you can likely expense. 😉 

THE BAD
Clinical Trials

Xilio Therapeutics' vilastobart (anti-CTLA-4) mixed Ph2 results in colorectal cancer sick stock by 30%
Monoclonal antibody, colorectal cancer - Read more

THE BAD
Earnings & Finances

Johnson & Johnson forecasts $2 billion sales drop due to Medicare Part D changes under Inflation Reduction Act's new drug pricing rules
Inflation reduction act, medicare, drug pricing - Read more

THE BAD
Lawsuits

Court rejects Vanda Pharamceuticals' claim that FDA violated the US Constitution by sharing drug specifications with generic competitors Lupin Pharmaceuticals and Teva Pharmaceuticals
Small molecule, schiz­o­phre­nia, sleep dis­or­der - Read more [Paywall]

THE BAD
Layoffs

Biogen drug discovery department layoffs
Drug discovery, neuropsychiatry - Read more

THE BAD
Mergers & Acquisition

Fosun International's $693 million buyout offer for remaining Henlius Biotech shares fails to secure shareholder approval
Antibody, biosimilar - Read more

THE UGLY
Adverse Events

Inhibrx Biosciences' colorectal cancer drug shows promising results but faces safety concerns after patient death in Ph1 trial
Tetravalent antibody, colorectal cancer - Read more

THE UGLY
Politics & Policy

Trump administration abruptly cancels multiple federal science meetings, including NIH grant reviews and vaccine advisory panels, causing concern
Meeting cancellations, scientific meeting - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

Last thing - if you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here